Pennisetum Purpureum in Sarcopenia Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to investigate the effects of Pennisetum purpureum health food supplementation on muscle mass and muscle strength.

Detailed Description
-----------------
All participants performed anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey before supplementation. Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference. The definition of insufficient muscle mass was based on the Asian working group for sarcopenia (AWGS) that skeletal muscle mass in extremities by dual-energy X-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women is a necessary condition, and one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than12 seconds. The anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey, were collected after 8 weeks and 12 weeks of supplementation.

Official Title
-----------------
Effects of Pennisetum Purpureum Health Food Supplementation on Muscle Mass and Muscle Strength

Conditions
-----------------
Sarcopenia

Intervention / Treatment
-----------------
* Dietary Supplement: Pennisetum purpureum
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult between 18-75 years old skeletal muscle mass in extremities by dual-energy X-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than 12 seconds Exclusion Criteria: The volunteers have history of cardiovascular, liver, kidney, and diabetes mellitus acute sport injury participated in any clinical trials or experimental research in the last 3 months before our experiment taking supplement during the experimental period did not maintain their regular eating habit or drink alcohol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pennisetum purpureum group<br> | Dietary Supplement: Pennisetum purpureum<br>* 300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks<br>|
| Placebo Comparator: Placebo group<br> | Dietary Supplement: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body height |  | Baseline (before supplementation) | 
| Body height |  | 8 weeks of supplementation | 
| Body height |  | 12 weeks of supplementation | 
| Body weight |  | Baseline (before supplementation) | 
| Body weight |  | 8 weeks of supplementation | 
| Body weight |  | 12 weeks of supplementation | 
| BMI (body mass index) |  | Baseline (before supplementation) | 
| BMI (body mass index) |  | 8 weeks of supplementation | 
| BMI (body mass index) |  | 12 weeks of supplementation | 
| Systolic blood pressure |  | Baseline (before supplementation) | 
| Systolic blood pressure |  | 8 weeks of supplementation | 
| Systolic blood pressure |  | 12 weeks of supplementation | 
| Diastolic blood pressure |  | Baseline (before supplementation) | 
| Diastolic blood pressure |  | 8 weeks of supplementation | 
| Diastolic blood pressure |  | 12 weeks of supplementation | 
| ASM (Appendicular Skeletal Muscle Mass) |  | 12 weeks of supplementation | 
| ASM (Appendicular Skeletal Muscle Mass) |  | 8 weeks of supplementation | 
| Upper Arm Circumference |  | Baseline (before supplementation) | 
| Upper Arm Circumference |  | 8 weeks of supplementation | 
| Upper Arm Circumference |  | 12 weeks of supplementation | 
| Thigh Circumference |  | Baseline (before supplementation) | 
| Thigh Circumference |  | 8 weeks of supplementation | 
| Thigh Circumference |  | 12 weeks of supplementation | 
| Grip Strength |  | Baseline (before supplementation) | 
| Grip Strength |  | 8 weeks of supplementation | 
| Grip Strength |  | 12 weeks of supplementation | 
| 10-Meter Walk Test |  | Baseline (before supplementation) | 
| 10-Meter Walk Test |  | 8 weeks of supplementation | 
| 10-Meter Walk Test |  | 12 weeks of supplementation | 
| Testosterone level |  | Baseline (before supplementation) | 
| Testosterone level |  | 8 weeks of supplementation | 
| Testosterone level |  | 12 weeks of supplementation | 
| Cortisol level |  | Baseline (before supplementation) | 
| Cortisol level |  | 8 weeks of supplementation | 
| Cortisol level |  | 12 weeks of supplementation | 
| Growth Hormone level |  | Baseline (before supplementation) | 
| Growth Hormone level |  | 8 weeks of supplementation | 
| Growth Hormone level |  | 12 weeks of supplementation | 
| Insulin-like Growth Factor-1 |  | Baseline (before supplementation) | 
| Insulin-like Growth Factor-1 |  | 8 weeks of supplementation | 
| Insulin-like Growth Factor-1 |  | 12 weeks of supplementation | 
| follistain level |  | Baseline (before supplementation) | 
| follistain level |  | 8 weeks of supplementation | 
| follistain level |  | 12 weeks of supplementation | 
| myostain level |  | Baseline (before supplementation) | 
| myostain level |  | 8 weeks of supplementation | 
| myostain level |  | 12 weeks of supplementation |